Mineralys Therapeutics(MLYS)

Search documents
Mineralys Therapeutics(MLYS) - 2023 Q2 - Quarterly Report
2023-08-07 21:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1966887 (Stat ...
Mineralys Therapeutics(MLYS) - 2023 Q1 - Quarterly Report
2023-05-15 21:25
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1966887 (Sta ...
Mineralys Therapeutics (MLYS) Investor Presentation - Slideshow
2023-03-29 12:38
| --- | --- | --- | |-------|-------|-------| | | | | | | | | Lorundrostat substantially lowered BP compared to placebo by 9.1mmHg at 50mg QD and 10.0 at 100mg QD in uncontrolled and resistant hypertension. Lorundrostat Was Effective At Lowering Blood Pressure In Individuals With Uncontrolled And Resistant Hypertension All measures represent mean placebo-adjusted reductions. No notable effect on cortisol and moderate increase in potassium * Part 1 of Phase 2 Target-HTN Proof of Concept Trial Mineralys Thera ...
Mineralys Therapeutics(MLYS) - 2022 Q4 - Annual Report
2023-03-15 21:17
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ____________________________________ (Exact name of registrant as specified in its charter) (Primary Standard Industrial Delaware 2834 84-1966887 (I.R.S. Employer Identification No.) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tra ...